The different roles played by CerK in more aggressive metastatic BC cell lines with respect to non-metastatic cell lines have been substantiated in a recent and exhaustive study, reporting a detailed analysis of SL profiles and the transcriptional and translational expressions of corresponding metabolizing enzymes in TPBC BT-474 and TNBC MDA-MB-231 cells: each cell type exhibited a unique SL profile, likely responsible for their unique phenotypic behavior, and common enzymes, including CerK, were dysregulated in both cell lines [61]. The gene discussed is CERK; the disease is breast cancer.